Fingolimod does not enhance cerebellar remyelination in the cuprizone model
Alme, Maria Nordheim; Nystad, Agnes Elisabeth; Bø, Lars; Myhr, Kjell-Morten; Vedeler, Christian A.; Wergeland, Stig; Torkildsen, Øivind
Journal article
Published version
Åpne
Permanent lenke
https://hdl.handle.net/1956/10915Utgivelsesdato
2015-08Metadata
Vis full innførselSamlinger
Originalversjon
https://doi.org/10.1016/j.jneuroim.2015.06.006Sammendrag
Fingolimod (FTY720) is approved for treatment of relapsing–remitting multiple sclerosis. In vitro studies have found that fingolimod stimulates remyelination in cerebellar slices, but in vivo animal studies have not detected any positive effect on cerebral remyelination. The discrepant findings could be a result of different mechanisms underlying cerebral and cerebellar remyelination. The cuprizone model for de- and remyelination was used to evaluate whether fingolimod had an impact on cerebellar remyelination in vivo. We found that fingolimod did not have any effect on cerebellar remyelination, number of mature oligodendrocytes, microglia or astrocytes when fed after cuprizone exposure.